Savolitinib
Chemical compound
![]() | |
Clinical data | |
---|---|
Other names | Volitinib |
Identifiers | |
| |
CAS Number |
|
ChemSpider |
|
UNII |
|
KEGG |
|
ChEBI |
|
CompTox Dashboard (EPA) |
|
ECHA InfoCard | 100.238.920 ![]() |
Chemical and physical data | |
Formula | C17H15N9 |
Molar mass | 345.370 g·mol−1 |
3D model (JSmol) |
|
| |
InChI
|
Savolitinib is an experimental small molecule inhibitor of c-Met. It is being investigated for the treatment of cancer by AstraZeneca.[1] It is in phase II clinical trials for adenocarcinoma, non-small cell lung cancer, and renal cell carcinoma.[2] It has been given conditional approval for these indication in China.[3]
References
- ^ "Savolitinib" (PDF). Statement on a Nonproprietary Name Adopted by the USAN Council. American Medical Association. 26 October 2016.
- ^ "Savolitinib - AstraZeneca/Hutchison China MediTech Limited". AdisInsight. Springer Nature Switzerland AG.
- ^ Markham A (September 2021). "Savolitinib: First Approval". Drugs. 81 (14): 1665–1670. doi:10.1007/s40265-021-01584-0. PMID 34455538. S2CID 237344020.
External links
- "Savolitinib". Drug Information Portal. U.S. National Library of Medicine.
- v
- t
- e
AstraZeneca
- Acalabrutinib
- Anastrozole
- Andexanet alfa
- Anifrolumab
- Asfotase alfa
- Atenolol
- Benralizumab
- Bicalutamide
- Brompheniramine
- Budesonide
- Budesonide/formoterol
- Budesonide/glycopyrronium bromide/formoterol
- Candesartan
- Dapagliflozin
- Disufenton sodium
- Durvalumab
- Eculizumab
- Esomeprazole
- Exenatide
- FluMist
- Fulvestrant
- Gefitinib
- Glycopyrronium bromide/formoterol
- Goserelin
- Isosorbide mononitrate
- Metoprolol
- Motavizumab
- Olaparib
- Omeprazole
- Osimertinib
- Palivizumab
- Propofol
- Quetiapine
- Ravulizumab
- Roflumilast
- Rosuvastatin
- Roxadustat
- Salbutamol/budesonide
- Savolitinib
- Saxagliptin
- Sebelipase alfa
- Selumetinib
- Sodium zirconium cyclosilicate
- Tamoxifen
- Ticagrelor
- Tixagevimab/cilgavimab
- Trastuzumab deruxtecan
- Vandetanib
- Vaxzevria
- Ximelagatran
- Zafirlukast
- Zolmitriptan
acquired companies
- Tom McKillop
- Louis Schweitzer
Category
Commons